OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
14
Results
Show all
Save search
Copy query
Show results for
Unknown
(14)
Release Date
2023
(5)
2022
(5)
2021
(3)
2025
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
Not available
S-EPMC8693692
|
biostudies-literature
Cite
Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery.
Not available
S-EPMC8855527
|
biostudies-literature
Cite
Simvastatin in Critically Ill Patients with Covid-19.
Not available
S-EPMC10755839
|
biostudies-literature
Cite
GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19.
Not available
S-EPMC10208981
|
biostudies-literature
Cite
A second update on mapping the human genetic architecture of COVID-19.
Not available
S-EPMC10482689
|
biostudies-literature
Cite
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8084355
|
biostudies-literature
Cite
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8830904
|
biostudies-literature
Cite
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8598213
|
biostudies-literature
Cite
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
Not available
S-EPMC9333998
|
biostudies-literature
Cite
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC10957483
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets